IFIH1 and dermatomyositis: RV-LAS, a validated marker of RV contractility in conditions ranging from type 2 diabetes to non-ischemic cardiomyopathy (11, 16), was consistently reduced in anti-MDA5+ DM patients, confirming subclinical RV dysfunction.